Monday, 26 Aug 2019

You are here

Adalimumab FDA Approved for Hidradenitis Suppurativa

Abbvie announced on 9/10/15 that adalimumab (Humira) has been FDA approved for the treatment of moderate to severe hidradenitis suppurativa (HS) and is now the first and only FDA-approved therapy for adults with HS.

Approval is based on the results of two pivotal Phase 3 studies, PIONEER I and PIONEER II, that included 633 people with moderate to severe HS. Both studies showed that adalimumab significantly reduced the total number of abscesses and inflammatory nodules compared with patients given placebo. No new safety risks were identified in these trials.

The European Commission approved adalimumab for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic treatment.

The author has no conflicts of interest to disclose related to this subject

Rheumatologists' Comments

I have treated a 58 y/o gentleman with Hydroadenitis associated arthritis using Inflixamab for approximately 8 years now. Excellent response of the arthritis and near complete resolution of skin lesions. Occasional mild skin lesion if infusion is delayed, which occurs due to pts. schedule, however, through the years there has been absolutely no need further surgical intervention regarding the Hydroadenitis. Prior to biological therapy, he frequently required surgical abscess resection, and just prior initiation of Inflixamab therapy, had a complete axillary dissection.

More Like This

Enbrel Patent Battle Won by Amgen

The ugly, legal, financial underbelly of US biosimilar drug development showed up in court last Friday, when a U.S. judge upheld two of Amgen's patents for Enbrel, thwarting a legal challenge by Novartis/Sandoz over its etanercept-szzs biosimilar, Erelzi. 

Sandoz won FDA approval for their etanercept biosimilar in 2016, but has not been able to market Erelzi because of Amgen’s extended patent protection (till 2029).

TNF Inhibitor and Biologic Induced Psoriasis

Analysis of RA patients in the German biologics register, RABBIT, shows an increased risk of psoriasis with TNF inhibitor (TNFi) compared to csDMARDs and other non-TNFi biologics. 

Among RABBIT RA patients without (n = 14,525) or with a history of psoriasis (n = 375) they assessed the risk of incident psoriasis or flare according to what biologic or csDMARD taken.

FDA Approves Cimzia for Non-Radiographic Axial Spondyloarthritis

The U.S. Food and Drug Administration today approved Cimzia (certolizumab pegol) injection for treatment of adults with a certain type of inflammatory arthritis called non-radiographic axial spondyloarthritis (nr-axSpA), with objective signs of inflammation. This is the first time that the FDA has approved a treatment for nr-axSpA.

Lower TNF Inhibitor Persistence in Spondylitis

A claims data analysis shows that only one-third of ankylosing spondylitis (AS) treated with tumor necrosis factor inhibitors (TNFi) therapy remain on their initial drug in the 2 years post initiation.

The Risk of Tuberculosis with TNF Inhibitors

A study from Turkey shows that among 2117 patients treated with a TNF inhibitor (TNFi) the risk of developing TB was 6 fold higher in those treated with a TNFi compared to non-users.

This retrospective cohort study included patients with rheumatoid arthritis (RA), ankylosing spondylitis, juvenile idiopathic arthritis or psoriatic arthritis (PsA) that treated with or without TNFI. The calculated the 2-year RR of TB after TNFi.